Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases.
Sarissa’s Alkermes board replacements largely fail to win support from shareholder firms, which cite Biogen board moves
Alex Denner, the investor behind the activist firm Sarissa Capital Management, is not winning much support for his board upheaval plans at Irish drugmaker Alkermes.